PHENTERMINE HYDROCHLORIDE Drug Patent Profile

When do Phentermine Hydrochloride patents expire, and when can generic versions of Phentermine Hydrochloride launch?

Phentermine Hydrochloride is a drug marketed by Abc Holding, Able, Aurolife Pharma Llc, Barr, Camall, Chartwell Rx, Duramed Pharms Barr, Elite Labs, Elite Labs Inc, Invagen Pharms, Ivax Pharms, Kvk Tech, Lannett, Lannett Co Inc, Nuvo Pharm, Sandoz, Sun Pharm Industries, Teva, Tg United Inc, Upsher Smith Labs, Usl Pharma, Vitarine, Watson Labs, Zydus Pharms, Actavis Elizabeth, Aurobindo Pharma Ltd, Ingenus Pharms Llc, Kvk Tech Inc, Prinston Inc, Puracap Labs Blu, Sandoz Inc, Sun Pharm Inds Inc, Actavis Labs Fl Inc, and Dr Reddys Labs Sa. and is included in eighty-nine NDAs.

The generic ingredient in PHENTERMINE HYDROCHLORIDE is phentermine hydrochloride; topiramate. There are seventeen drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the phentermine hydrochloride; topiramate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Phentermine Hydrochloride

A generic version of PHENTERMINE HYDROCHLORIDE was approved as phentermine hydrochloride; topiramate by ACTAVIS LABS FL INC on June 25^th, 2024.

Summary for PHENTERMINE HYDROCHLORIDE

US Patents:	0
Applicants:	34
NDAs:	89
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for PHENTERMINE HYDROCHLORIDE

Paragraph IV (Patent) Challenges for PHENTERMINE HYDROCHLORIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
SUPRENZA	Orally Disintegrating Tablets	phentermine hydrochloride	37.5 mg	202088	1	2013-03-22
SUPRENZA	Orally Disintegrating Tablets	phentermine hydrochloride	15 mg and 30 mg	202088	1	2012-10-19

US Patents and Regulatory Information for PHENTERMINE HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Chartwell Rx	PHENTERMINE HYDROCHLORIDE	phentermine hydrochloride	TABLET;ORAL	083923-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Actavis Labs Fl Inc	PHENTERMINE HYDROCHLORIDE AND TOPIRAMATE	phentermine hydrochloride; topiramate	CAPSULE, EXTENDED RELEASE;ORAL	204982-004	Jun 25, 2024	AB	RX	No	No
Nuvo Pharm	PHENTERMINE HYDROCHLORIDE	phentermine hydrochloride	CAPSULE;ORAL	205019-001	Dec 5, 2014	AA	RX	No	No

Investment Scenario and Fundamentals Analysis for Phentermine Hydrochloride

Last updated: February 20, 2026

What is the current market position of phentermine hydrochloride?

Phentermine hydrochloride (HCl) is a sympathomimetic agent approved primarily for short-term weight management. It is classified as a Schedule IV controlled substance in the U.S. due to its potential for abuse and dependency. Market dynamics are influenced by regulatory status, patent landscape, manufacturing capacity, and demand within obesity treatment segments.

What are the key production and regulatory factors?

Phentermine HCl is mostly produced by generic manufacturers with established synthesis pathways. Key regulatory considerations include:

• FDA Approval: Approved for short-term weight loss under prescription. No recent changes in approval status.
• Patent Landscape: The original patent expired in the early 2000s; manufacturers rely on generic production.
• Controlled Substance Regulations: Stringent regulations in the U.S. and several other jurisdictions impact manufacturing and distribution.

What is the global demand and supply outlook?

Demand stems from obesity therapy, with an estimated market size of approximately USD 700 million in 2022 (ResearchAndMarkets, 2022). Growth rates are modest, averaging 3-4% annually, constrained by regulatory restrictions and the commoditized nature of generics.

Supply is highly fragmented, with key players including Teva Pharmaceuticals, Mylan, and Cipla. Supply disruptions are rare but can impact prices and availability due to regulatory compliance costs or manufacturing issues.

How does competitive landscape influence investment?

The product is a low-margin, highly generic market. Barriers for new entrants are high in the form of regulatory compliance and manufacturing scale but few innovation drivers exist, limiting premium pricing prospects.

Recent trends include:

• Formulation innovations: Limited, as immediate-release forms dominate.
• Alternative weight management drugs: Increasing competition from GLP-1 receptor agonists (e.g., semaglutide) affects prescription volumes.
• Regulatory shifts: Stringent control over controlled substances could tighten supply chains, impacting volume and pricing.

What are the key financial metrics for potential investment?

Financial data is limited due to the drug's status as a generic. Typical metrics include:

Metric	Industry average	Current Approximate Range (USD)	Source
Price per tablet	USD 0.05–0.10	USD 0.08	(IBISWorld, 2022)
Market size	USD 700 million	USD 650–750 million	(ResearchAndMarkets, 2022)
Production costs	20–30% of price	USD 0.02–0.03 per tablet	Industry estimates
EBITDA margin	10–15%	Presumed low due to commoditization	Industry reports

Potential investors should consider:

• Patent expiry impact: No patent risk limits future profitability but supports price competition.
• Manufacturing scale: Economies of scale reduce costs but require significant capital.
• Regulatory compliance costs: Ongoing investments are necessary to maintain manufacturing licenses.

What are the risks associated with investing in phentermine HCl?

Major risks include:

• Regulatory restrictions: Tighter control over controlled substances could limit production or increase compliance costs.
• Market decline: Competition from newer classes like GLP-1 agents diminishes prescription volume.
• Pricing pressure: High generic competition drives prices down.
• Supply chain disruptions: Regulatory or manufacturing issues may cause shortages, affecting revenue.

How do future developments impact investment potential?

Future prospects are limited to incremental volume growth and manufacturing efficiencies. No significant innovation or patent protection exists, which caps upside potential. The drug's role in obesity treatment may be affected by shifts toward newer, more effective therapies with better safety profiles.

What should investors monitor moving forward?

Investors should track:

• Regulatory changes affecting controlled substances.
• Trends in obesity drug market share.
• Production capacity and costs for key competitors.
• Shifts toward alternative weight management therapies.
• Global market expansions, especially in emerging markets with less regulatory rigidity.

Key Takeaways

• Pharmacological, regulatory, and market factors create a low-margin, competitive environment.
• Demand growth remains modest, constrained by market saturation and newer therapies.
• Regulatory risks tied to controlled substance classification heighten operational complexity.
• Supply is concentrated among few producers, but barriers to entry limit new competition.
• Future upside is limited, with primary drivers being market share retention and cost efficiencies.

FAQs

1. Is phentermine hydrochloride a viable long-term investment?

Limited. The market is mature with low growth prospects, high regulatory risks, and competition from newer therapies.

2. How do regulatory constraints affect supply?

Stringent controls on Schedule IV substances increase compliance costs and operational complexity, potentially causing supply chain disruptions.

3. Are there opportunities for differentiation?

Minimal. The drug is a commoditized product with no new formulations or delivery mechanisms widely available.

4. What impact does competition from newer drugs have?

It reduces prescription volumes and market share, especially as GLP-1 receptor agonists offer superior safety and efficacy for obesity.

5. How does the patent landscape influence profitability?

The absence of patent protection favors generics, leading to price erosion but also enabling broad market access.

References

1. ResearchAndMarkets. (2022). Global weight loss drugs market report.
2. IBISWorld. (2022). Industry report on generic pharmaceuticals.
3. Food and Drug Administration. (2020). Drug Approvals and Regulatory Policies.
4. U.S. Drug Enforcement Administration. (2021). Controlled Substance Act regulations.